• Visitors Now:
  • Total Visits:
  • Total Stories:
Profile image
By ProactiveInvestors
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Nektar Therapeutics surges on positive findings for its pain treatment

Monday, March 20, 2017 12:30
% of readers think this story is Fact. Add your two cents.

Nektar Therapeutics (NASDAQ: NKTR ) shares surged almost 43% to US$22.13 in New York as it posted positive findings of a Phase 3 efficacy study of NKTR-181 – its opioid analgesic for treating pain.

The candidate is designed to manage pain without high levels of euphoria that can lead to addiction with standard opioids, and it met its primary and secondary endpoints.

NKTR-181 also demonstrated a favorable safety profile, Nektar said.

The Food and Drug Administration  (FDA) have granted the investigational medicine “fast track” designation for the treatment of moderate to severe chronic pain.

“The data from this efficacy study are extremely important because they demonstrate that NKTR-181 produces strong analgesia in patients suffering from chronic pain while NKTR-181 has also demonstrated significantly lower abuse potential than oxycodone in a human abuse potential study,” said Martin Hale, the clinical investigator of the study and medical director at Gold Coast Research

He added: “The data for NKTR-181 suggest that it is a transformational pain medicine that could fundamentally change how we treat patients with chronic pain conditions.”

Story by ProactiveInvestors

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Today's Top Stories

Most Recent Stories



Email this story
Email this story
Share This Story:
Print this story
Email this story
Share on Tumblr

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.